BiotechTube

Afamelanotide

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria

Conditions

Erythropoietic Protoporphyria

Trial Timeline

Jul 11, 2011 → Feb 27, 2014

NCT ID
NCT04578496

About Afamelanotide

Afamelanotide is a phase 3 stage product being developed by Clinuvel Pharmaceuticals for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT04578496. Target conditions include Erythropoietic Protoporphyria.

What happened to similar drugs?

0 of 4 similar drugs in Erythropoietic Protoporphyria were approved

Approved (0) Terminated (0) Active (4)
🔄Placebo + DISC-1459Disc MedicinePhase 3
🔄Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
🔄Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
🔄Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT05210582Phase 2UNKNOWN
NCT05370235Phase 2UNKNOWN
NCT05368857Phase 1Completed
NCT05159752Phase 2UNKNOWN
NCT04962503Phase 2Completed
NCT01382589Phase 2Completed
NCT04578496Phase 3Completed
NCT01430195Phase 1Completed
NCT04943159Phase 2Completed
NCT00859534Phase 2Completed

Competing Products

8 competing products in Erythropoietic Protoporphyria

See all competitors
ProductCompanyStageHype Score
DISC-1459 + DISC-1459 + PlaceboDisc MedicinePhase 2
29
Placebo + DISC-1459Disc MedicinePhase 3
41
DISC-1459 + DISC-1459Disc MedicinePhase 2/3
39
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
34
Afamelanotide 16mg implantClinuvel PharmaceuticalsPhase 1/2
26
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
34
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
29
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
34